Get started
Author

Robert A.B. van Waterschoot

Observed names: R. A. B. van Waterschoot, Robert A. B. Van Waterschoot, Robert A. B. van Waterschoot, Robert A.B. Van Waterschoot, Robert AB. van Waterschoot, Robert B. van Waterschoot, Robert van Waterschoot
Observed institutions: F. Hoffmann-La Roche AG, Merck & Co., Inc., Rahway, NJ, USA (United States), Genentech, Utrecht University, University of Washington, Slotervaartziekenhuis, The Netherlands Cancer Institute, Bristol-Myers Squibb (United States), GlaxoSmithKline (United States), AbbVie (Germany), Instituto Tecnológico Superior de Teziutlán, Janssen Research & Development (United States), Vrije Universiteit Amsterdam
OpenAlex ID: A5064255458
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism
2007 · Antonius E. van Herwaarden, Els Wagenaar, et al. · Journal of Clinical Investigation · 241
PDF
Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
2010 · Jurjen S. Lagas, Robert A.B. van Waterschoot, et al. · Molecular Cancer Therapeutics · 189
Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
2009 · Jurjen S. Lagas, Robert A.B. van Waterschoot, et al. · Clinical Cancer Research · 179
A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice
2011 · Robert A.B. van Waterschoot, Alfred H. Schinkel · Pharmacological Reviews · 138
Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes
2007 · Robert A.B. van Waterschoot, Antonius E. van Herwaarden, et al. · Molecular Pharmacology · 114
Absence of Both Cytochrome P 450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity
2009 · Robert A.B. van Waterschoot, Jurjen S. Lagas, et al. · Cancer Research · 97
Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam
2009 · Robert A.B. van Waterschoot, Rogier W. Rooswinkel, et al. · Drug Metabolism and Disposition · 66
P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin
2008 · Jurjen S. Lagas, Rolf W. Sparidans, et al. · Antimicrobial Agents and Chemotherapy · 63
How important is intestinal cytochrome P450 3A metabolism?
2009 · Antonius E. van Herwaarden, Robert A.B. van Waterschoot, et al. · Trends in Pharmacological Sciences · 57
Individual and combined roles of CYP3A, P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel
2010 · Robert A.B. van Waterschoot, Jurjen S. Lagas, et al. · International Journal of Cancer · 52
Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver
2008 · Robert A. B. van Waterschoot, Rogier W. Rooswinkel, et al. · The FASEB Journal · 51
Molecular Modeling-Guided Site-Directed Mutagenesis of Cytochrome P450 2D6
2006 · Chris de Graaf, Chris Oostenbrink, et al. · Current Drug Metabolism · 44
Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins
2014 · Laurent Salphati, Xiaoyan Chu, et al. · Drug Metabolism and Disposition · 43
Importance of target-mediated drug disposition for small molecules
2018 · Dennis A. Smith, Robert A.B. van Waterschoot, et al. · Drug Discovery Today · 38
Impact of target interactions on small-molecule drug disposition: an overlooked area
2018 · Robert A. B. van Waterschoot, Neil J. Parrott, et al. · Nature Reviews Drug Discovery · 36
PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide
2008 · Christian Zimmermann, Robert A.B. van Waterschoot, et al. · European Journal of Pharmaceutical Sciences · 35
P-Glycoprotein, Multidrug-Resistance Associated Protein 2, Cyp3a, and Carboxylesterase Affect the Oral Availability and Metabolism of Vinorelbine
2012 · Jurjen S. Lagas, Carola W.N. Damen, et al. · Molecular Pharmacology · 31
Abstract LB-085: RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment
2016 · Gabor Gyulveszi, Christine Fischer, et al. · Cancer Research · 26
An Integrated Pharmacokinetic Model for the Influence of CYP3A4 Expression on the In Vivo Disposition of Lopinavir and Its Modulation by Ritonavir
2010 · Rob ter Heine, Robert A.B. Van Waterschoot, et al. · Journal of Pharmaceutical Sciences · 18
ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity
2009 · Robert A.B. van Waterschoot, Rhandy M. Eman, et al. · Clinical Cancer Research · 16
Topological role of cytochrome P450 2D6 active site residues
2006 · Robert A.B. van Waterschoot, Peter H.J. Keizers, et al. · Archives of Biochemistry and Biophysics · 9
From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies
2011 · S. L. W. Koolen, R. A. B. van Waterschoot, et al. · The Journal of Clinical Pharmacology · 5
Supplementary Figure 2 from Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
2023 · Jurjen S. Lagas, Robert A.B. van Waterschoot, et al.
Supplementary Figure Legends 1-2 from Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
2023 · Jurjen S. Lagas, Robert A.B. van Waterschoot, et al.
Supplementary Figure 1 from Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
2023 · Jurjen S. Lagas, Robert A.B. van Waterschoot, et al.
Works count: 42
Citation count: 1,548
H-index: 18
I10-index: 20
Year
Topic
Type